關鍵詞： 艾爾健 SkinMedica
2012年12月24日訊 /生物谷BIOON/ --艾爾健(Allergan)宣布,，已完成對SkinMedica公司局部美學（ topical aesthetics）皮膚護理業(yè)務的收購，包括各種“醫(yī)生配發(fā)（physician despensed）”的非處方美學護膚品及處方產品,。此次收購耗資3.5億美元,，Allergan計劃將SkinMedica作為一個獨立的全球性業(yè)務進行運作,，同時將充分利用Allergan現有的首選客戶程序及SkinMedica產品線。（生物谷bioon.com）
英文原文：
ViiV Healthcare today announced the submission of regulatory applications in the European Union (EU), United States (US) and Canada for the investigational integrase inhibitor dolutegravir (S/GSK1349572) for the treatment of HIV infection in adults and adolescents, specifically:
A Marketing Authorisation Application to the European Medicines Agency for dolutegravir for the treatment of HIV infection in adults and children aged 12 years and older.
A New Drug Application to the US Food and Drug Administration for dolutegravir for the treatment of HIV infection in adults and children aged 12 years and older.
A New Drug Submission to Health Canada for dolutegravir for the treatment of HIV infection in adults and children aged 12 years and older.
"These regulatory submissions are an important step for ViiV Healthcare, representing our commitment as a company to bring new treatments to people living with HIV." said John Pottage, MD, Chief Scientific and Medical Officer, ViiV Healthcare. "We are encouraged by the comprehensive data package supporting dolutegravir, and believe that it has the potential to offer an important new option for the treatment of both naïve and treatment-experienced patients with HIV."
